COLL

Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Peers: AMRX ANIP ARDX ASRT ASND EYPT HRTX LXRX PCRX PTGX

| Held by: IJR VTI IWM VXF AVUV SPSM IJT PJP IWO CALF

Scroll to Statements

Index	RUT	P/E	20.75	EPS (ttm)	1.72	Insider Own	3.91%	Shs Outstand	31.71M	Perf Week	-4.43%
Market Cap	1.13B	Forward P/E	4.96	EPS next Y	7.18	Insider Trans	-9.88%	Shs Float	30.51M	Perf Month	-21.33%
Enterprise Value	1.66B	PEG	-	EPS next Q	1.81	Inst Own	118.75%	Short Float	15.07%	Perf Quarter	-26.34%
Income	62.87M	P/S	1.45	EPS this Y	10.04%	Inst Trans	0.10%	Short Ratio	9.90	Perf Half Y	-4.56%
Sales	780.57M	P/B	3.74	EPS next Y	-12.02%	ROA	3.75%	Short Interest	4.60M	Perf YTD	-23.07%
Book/sh	9.51	P/C	2.78	EPS next 5Y	-3.25%	ROE	23.70%	52W High	50.79 -29.86%	Perf Year	20.91%
Cash/sh	12.80	P/FCF	3.45	EPS past 3/5Y	- 17.92%	ROIC	5.21%	52W Low	23.23 53.34%	Perf 3Y	46.58%
Dividend Est.	-	EV/EBITDA	4.05	Sales past 3/5Y	18.94% 20.28%	Gross Margin	59.35%	Volatility	3.80% 3.77%	Perf 5Y	44.27%
Dividend TTM	-	EV/Sales	2.13	EPS Y/Y TTM	-7.25%	Oper. Margin	23.58%	ATR (14)	1.62	Perf 10Y	111.65%
Dividend Ex-Date	-	Quick Ratio	1.48	Sales Y/Y TTM	23.62%	Profit Margin	8.05%	RSI (14)	25.07	Recom	1.50
Dividend Gr. 3/5Y	- -	Current Ratio	1.57	EPS Q/Q	31.51%	SMA20	-12.44%	Beta	0.74	Target Price	53.83
Payout	0.00%	Debt/Eq	3.10	Sales Q/Q	12.92%	SMA50	-19.35%	Rel Volume	1.44	Prev Close	34.50
Employees	423	LT Debt/Eq	3.00	Earnings	Feb 26 BMO	SMA200	-8.24%	Avg Volume	464.57K	Price	35.62
IPO	May 07, 2015	Option/Short	Yes / Yes	EPS/Sales Surpr.	-4.64% -0.44%	Trades		Volume	670,252	Change	3.25%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-09-25	Initiated	Barclays	Overweight	$58
Jan-10-25	Upgrade	Needham	Hold → Buy	$46
Jul-30-24	Upgrade	H.C. Wainwright	Neutral → Buy	$47
Jun-07-24	Upgrade	Jefferies	Hold → Buy	$41 → $44
May-10-24	Downgrade	Piper Sandler	Overweight → Neutral	$39
May-10-24	Downgrade	Needham	Buy → Hold
Jan-04-24	Downgrade	Jefferies	Buy → Hold	$30 → $37
Aug-25-23	Reiterated	Needham	Buy	$35 → $36
May-02-23	Resumed	Jefferies	Buy	$30
Aug-08-22	Downgrade	H.C. Wainwright	Buy → Neutral
Feb-15-22	Upgrade	Cantor Fitzgerald	Neutral → Overweight	$18 → $26
Aug-06-21	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Jan-11-21	Reiterated	H.C. Wainwright	Buy	$29 → $33
Jul-14-20	Initiated	BWS Financial	Sell	$8
May-27-20	Initiated	Guggenheim	Neutral
Feb-19-20	Resumed	Jefferies	Buy	$43
Oct-30-19	Reiterated	Needham	Buy	$33 → $25
May-03-19	Resumed	H.C. Wainwright	Buy	$23
Apr-12-19	Resumed	Janney	Buy	$29
Mar-20-19	Initiated	SunTrust	Hold	$22

Show Previous Ratings

Mar-10-26 09:04AM	Collegium Pharmaceutical, Inc. (COLL) Surged Following Record Quarterly Results (Insider Monkey)
Mar-05-26 08:00AM	Collegium to Present New Real-World Data at PainConnect 2026 (GlobeNewswire) -5.88%
Mar-03-26 08:00AM	Paris Hilton Shares Her Experience with JORNAY PM and Launches New 'Embrace Your Sparkle' Campaign with Collegium to Empower the ADHD Community (GlobeNewswire)
Mar-02-26 08:00AM	Collegium to Participate in Upcoming Investor Conferences (GlobeNewswire)
Feb-27-26 03:20PM	Why Collegium Pharmaceutical (COLL) Stock Is Trading Lower Today (StockStory) -5.77%
04:32PM	Loading…
Feb-26-26 04:32PM	Collegium Pharmaceutical, Inc. Q4 2025 Earnings Call Summary (Moby)
04:13PM	Collegium Pharmaceutical Inc (COLL) Q4 2025 Earnings Call Highlights: Record Revenue Growth and ... (GuruFocus.com)
12:30PM	Collegium Pharmaceutical (COLL) Reports Q4 Earnings: What Key Metrics Have to Say (Zacks)
12:15PM	Collegium Pharmaceutical (COLL) Q4 Earnings and Revenues Miss Estimates (Zacks)
09:16AM	Collegium Pharmaceutical Q4 Earnings Call Highlights (MarketBeat)
07:53AM	Collegium Pharmaceutical: Q4 Earnings Snapshot (Associated Press Finance)
07:36AM	Collegium Pharmaceutical's (NASDAQ:COLL) Q4 CY2025 Earnings Results: Revenue In Line With Expectations (StockStory)
07:30AM	Collegium Reports Fourth Quarter and Full-Year 2025 Financial Results (GlobeNewswire)
Feb-24-26 10:07PM	Collegium Pharmaceutical (COLL) Q4 Earnings: What To Expect (StockStory)
10:00AM	Rigel Pharmaceuticals (RIGL) Earnings Expected to Grow: Should You Buy? (Zacks)
08:00AM	Loading…
Feb-23-26 08:00AM	Boston Legacy FC Announces Sensory Room Sponsorship with Collegium Pharmaceutical (GlobeNewswire)
Feb-19-26 10:00AM	Collegium Pharmaceutical (COLL) Earnings Expected to Grow: What to Know Ahead of Next Week's Release (Zacks)
09:53AM	Collegium Pharmaceutical to Report Q4 Earnings: What's in the Cards? (Zacks)
08:15AM	Madrigal (MDGL) Reports Q4 Loss, Beats Revenue Estimates (Zacks)
Feb-18-26 04:07AM	Collegium Pharmaceutical, Inc. (COLL) Gains Momentum on Jornay PM, Truist Highlights Robust Pain Portfolio (Insider Monkey)
Feb-12-26 08:00AM	Collegium to Report Fourth Quarter and Full-Year 2025 Financial Results on February 26, 2026 (GlobeNewswire)
Jan-15-26 08:00AM	Collegium to Present Four Real-World Data Posters at APSARD 2026 Annual Conference (GlobeNewswire)
Jan-12-26 09:40AM	Is Collegium Pharmaceutical (COLL) Stock Undervalued Right Now? (Zacks) +5.73%
Jan-08-26 08:00AM	Collegium Provides 2026 Financial Guidance and Business Update (GlobeNewswire)
Jan-05-26 09:54AM	Corcept (CORT) Surges 9.8%: Is This an Indication of Further Gains? (Zacks)
Jan-02-26 11:22AM	Here's Why Pediatrix Medical Can Be a Smart Addition to Your Portfolio (Zacks)
Dec-31-25 01:04PM	Why You Should Add Encompass Health to Your Portfolio Now (Zacks)
11:24AM	Here's Why You Should Retain Community Health Stock for Now (Zacks)
Dec-30-25 08:00AM	Collegium Announces the Closing of $980 Million Syndicated Credit Facility (GlobeNewswire)
Dec-28-25 11:01PM	2 Reasons to Avoid COLL and 1 Stock to Buy Instead (StockStory)
01:42PM	Loading…
Dec-26-25 01:42PM	Here's Why Investors Should Hold Ensign Group Stock for Now (Zacks)
Dec-22-25 09:40AM	Should Value Investors Buy Collegium Pharmaceutical (COLL) Stock? (Zacks)
09:40AM	Are Medical Stocks Lagging Actinium Pharmaceuticals (ATNM) This Year? (Zacks)
Dec-18-25 11:35PM	3 Unpopular Stocks We Find Risky (StockStory)
05:12AM	Best Value Stocks to Buy for Dec. 18 (Zacks)
Dec-14-25 10:31PM	Branded Pharmaceuticals Stocks Q3 Recap: Benchmarking Collegium Pharmaceutical (NASDAQ:COLL) (StockStory)
Dec-11-25 11:34PM	1 Growth Stock Set to Flourishand 2 Facing Challenges (StockStory)
12:51PM	MOH, Aeroflow Team Up to Offer Virtual Diabetes Care in South Carolina (Zacks)
Dec-04-25 09:40AM	Are Investors Undervaluing Collegium Pharmaceutical (COLL) Right Now? (Zacks)
09:40AM	Is Guardant Health (GH) Stock Outpacing Its Medical Peers This Year? (Zacks)
09:15AM	Collegium Pharmaceutical, Inc. (COLL) Hits Fresh High: Is There Still Room to Run? (Zacks)
Dec-03-25 03:45PM	Ensign Group Expands Foothold in Three U.S. States With Facility Buyouts (Zacks)
Nov-21-25 08:04AM	Why 2025 is a Dynamic and Transformative Year for Collegium (Zacks)
Nov-19-25 08:23AM	Collegium Pharma and Entegris have been highlighted as Zacks Bull and Bear of the Day (Zacks)
04:00AM	Bull of the Day: Collegium Pharmaceutical (COLL) (Zacks)
Nov-18-25 09:40AM	Is Collegium Pharmaceutical (COLL) Stock Undervalued Right Now? (Zacks)
09:40AM	Is Alnylam Pharmaceuticals (ALNY) Stock Outpacing Its Medical Peers This Year? (Zacks)
Nov-13-25 12:36AM	5 Revealing Analyst Questions From Collegium Pharmaceutical's Q3 Earnings Call (StockStory)
Nov-12-25 08:00AM	Collegium to Participate in Upcoming Investor Conferences (GlobeNewswire) +5.60%
Nov-07-25 09:50AM	COLL Q3 Deep Dive: Jornay PM Momentum and Pain Portfolio Drive Upgraded Outlook (StockStory)
Nov-06-25 03:25PM	Why Are Collegium Pharmaceutical (COLL) Shares Soaring Today (StockStory) +13.42%
02:09PM	Collegium Pharmaceutical Inc (COLL) Q3 2025 Earnings Call Highlights: Record Revenue and ... (GuruFocus.com)
09:30AM	Here's What Key Metrics Tell Us About Collegium Pharmaceutical (COLL) Q3 Earnings (Zacks)
08:50AM	Collegium Pharmaceutical (COLL) Q3 Earnings and Revenues Beat Estimates (Zacks)
08:09AM	Collegium Pharmaceutical (NASDAQ:COLL) Delivers Impressive Q3, Stock Jumps 12.1% (StockStory)
07:47AM	Collegium Pharmaceutical: Q3 Earnings Snapshot (Associated Press Finance)
07:30AM	Collegium Reports Third Quarter 2025 Financial Results; Raises 2025 Guidance (GlobeNewswire)
Nov-04-25 10:22PM	Earnings To Watch: Collegium Pharmaceutical (COLL) Reports Q3 Results Tomorrow (StockStory)
Oct-31-25 11:18AM	3 Explosive Stocks With High Short Interest (24/7 Wall St.)
Oct-30-25 10:00AM	Collegium Pharmaceutical (COLL) Earnings Expected to Grow: Should You Buy? (Zacks)
Oct-29-25 08:00AM	Paris Hilton Collaborates with Collegium Pharmaceutical to Share Her Personal ADHD Journey and Experience with Treatment (GlobeNewswire)
Oct-23-25 08:00AM	Collegium to Report Third Quarter 2025 Financial Results on November 6, 2025 (GlobeNewswire)
12:02AM	Collegium Pharmaceutical (COLL): Buy, Sell, or Hold Post Q2 Earnings? (StockStory)
Oct-22-25 08:00AM	Collegium Announces Poster Presentations at the American Academy of Child & Adolescent Psychiatry and Neuroscience Education Institute Conferences (GlobeNewswire)
Oct-13-25 08:00AM	Collegium to Celebrate 10-Year Anniversary with Nasdaq Opening Bell Ringing (GlobeNewswire)
Oct-08-25 11:25AM	Collegium Pharmaceutical, Inc. (COLL): A Bull Case Theory (Insider Monkey)
Oct-06-25 09:51AM	ESPR Settles Nexletol/Nexlizet Patent Litigation With RDY, Stock Up (Zacks)
Sep-25-25 07:19PM	Don't Overlook These 2 Highly Ranked Medical Stocks: COLL, MASI (Zacks)
12:00PM	All You Need to Know About Collegium Pharmaceutical (COLL) Rating Upgrade to Strong Buy (Zacks)
Sep-24-25 11:31PM	Branded Pharmaceuticals Stocks Q2 Highlights: Collegium Pharmaceutical (NASDAQ:COLL) (StockStory)
Sep-23-25 09:40AM	Should Value Investors Buy Collegium Pharmaceutical (COLL) Stock? (Zacks)
09:40AM	Are Medical Stocks Lagging Argenx (ARGX) This Year? (Zacks)
Sep-02-25 04:07AM	Collegium Pharmaceutical, Inc. (COLL) to Present 9 Pain Studies at PAINWeek 2025 (Insider Monkey)
Aug-29-25 05:07AM	Collegium Pharmaceutical, Inc. (COLL) Highlights Real-World Evidence at PAINWeek 2025 (Insider Monkey)
Aug-28-25 08:00AM	Collegium to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-25-25 08:00AM	Collegium to Present Nine Real-World Data Posters at PAINWeek 2025 Annual Meeting (GlobeNewswire)
Aug-14-25 01:34AM	The 5 Most Interesting Analyst Questions From Collegium Pharmaceutical's Q2 Earnings Call (StockStory)
Aug-12-25 03:25AM	COLL Q2 Deep Dive: Jornay Expansion Drives Revenue Guidance Increase, Margins Face Investment Pressure (StockStory)
Aug-11-25 09:33AM	Arm initiated, Adobe downgraded: Wall Street's top analyst calls (The Fly)
Aug-07-25 02:53PM	Collegium Pharmaceutical (NASDAQ:COLL) Exceeds Q2 Expectations, Stock Jumps 10.2% (StockStory) +10.72%
09:30AM	Compared to Estimates, Collegium Pharmaceutical (COLL) Q2 Earnings: A Look at Key Metrics (Zacks)
08:50AM	Collegium Pharmaceutical (COLL) Q2 Earnings and Revenues Surpass Estimates (Zacks)
07:49AM	Collegium Pharmaceutical: Q2 Earnings Snapshot (Associated Press Finance)
07:30AM	Collegium Reports Second Quarter 2025 Financial Results; Raises 2025 Outlook (GlobeNewswire)
Aug-06-25 05:50PM	Inotiv, Inc. (NOTV) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
Aug-05-25 11:11PM	Collegium Pharmaceutical (COLL) Q2 Earnings: What To Expect (StockStory)
10:00AM	Zevra Therapeutics (ZVRA) Reports Next Week: Wall Street Expects Earnings Growth (Zacks)
Jul-31-25 10:00AM	Collegium Pharmaceutical (COLL) Q2 Earnings Preview: What's in the Cards? (Zacks)
Jul-28-25 12:01AM	3 Reasons to Avoid COLL and 1 Stock to Buy Instead (StockStory)
Jul-25-25 09:55AM	Wall Street Analysts See a 33.91% Upside in Collegium Pharmaceutical (COLL): Can the Stock Really Move This High? (Zacks)
09:40AM	Are Investors Undervaluing Collegium Pharmaceutical (COLL) Right Now? (Zacks)
Jul-24-25 08:00AM	Collegium to Report Second Quarter 2025 Financial Results on August 7, 2025 (GlobeNewswire)
Jul-10-25 04:09PM	5 Hot Stocks With Summer Buybacks You Can Cash In On (MarketBeat)
Jul-07-25 08:00AM	Collegium Announces $150 Million Share Repurchase Program (GlobeNewswire)
Jul-01-25 02:42AM	Collegium Pharmaceutical Announces Share Repurchase Program Worth $25 Million (Insider Monkey)
Jun-30-25 06:24AM	5 Insightful Analyst Questions From Collegium Pharmaceutical's Q1 Earnings Call (StockStory)
Jun-10-25 04:40AM	COLL Q1 Earnings Call: ADHD Portfolio Drives Growth, Management Details Capital Deployment Priorities (StockStory)
Jun-05-25 11:31PM	Branded Pharmaceuticals Stocks Q1 In Review: Collegium Pharmaceutical (NASDAQ:COLL) Vs Peers (StockStory)
May-19-25 04:01PM	Collegium to Participate in Upcoming Investor Conferences (GlobeNewswire)
May-12-25 08:05AM	Collegium Announces $25 Million Accelerated Share Repurchase Program (GlobeNewswire)

Collegium Pharmaceutical, Inc. is a pharmaceutical company, which engages in development and planning to commercialize next generation, abuse-deterrent products for the treatment of patients suffering from chronic pain and other diseases. Its products include Xtampza ER, Nucynta ER and Nucynta IR, Belbuca, and Symproic. The company was founded by Michael Thomas Heffernan in April 2002 and is headquartered in Stoughton, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Dieter David	Officer	Mar 09 '26	Proposed Sale	36.65	6,224	228,110		Mar 09 10:39 AM
Dreyer Scott	EVP & Chief Commercial Officer	Mar 03 '26	Sale	40.41	49,976	2,019,437	71,770	Mar 05 04:29 PM
Dreyer Scott	Officer	Mar 03 '26	Proposed Sale	40.41	49,976	2,019,439		Mar 03 04:10 PM
RITA BALICE-GORDON	DIRECTOR	Dec 05 '25	Proposed Sale	47.03	3,650	171,673		Dec 17 04:01 PM
Dreyer Scott	EVP & Chief Commercial Officer	Dec 08 '25	Option Exercise	15.90	17,600	279,840	121,213	Dec 10 04:32 PM
Dreyer Scott	EVP & Chief Commercial Officer	Dec 08 '25	Sale	48.17	17,600	847,855	103,613	Dec 10 04:32 PM
Balice-Gordon Rita J.	Director	Dec 05 '25	Sale	47.03	3,650	171,673	52,629	Dec 09 04:22 PM
Dreyer Scott	Officer	Dec 08 '25	Proposed Sale	48.17	17,600	847,855		Dec 08 04:11 PM
Fallon John A.	Director	Nov 12 '25	Option Exercise	12.41	34,853	432,578	99,487	Nov 14 04:10 PM
Fallon John A.	Director	Nov 12 '25	Sale	47.21	34,853	1,645,536	64,634	Nov 14 04:10 PM
Fallon John A.	Director	Nov 12 '25	Proposed Sale	47.21	34,853	1,645,536		Nov 12 04:29 PM
Tupper Colleen	EVP & Chief Financial Officer	Nov 06 '25	Sale	40.53	30,000	1,215,753	126,667	Nov 07 04:23 PM
Tupper Colleen	Officer	Nov 06 '25	Proposed Sale	40.53	30,000	1,215,754		Nov 06 04:11 PM
Smith Thomas B	EVP and Chief Medical Officer	Aug 29 '25	Sale	38.42	17,478	671,576	70,264	Sep 03 04:56 PM
Smith Thomas B	Officer	Aug 29 '25	Proposed Sale	38.42	17,478	671,576		Aug 29 02:12 PM
Dreyer Scott	EVP & Chief Commercial Officer	Aug 18 '25	Option Exercise	21.34	16,389	349,741	120,002	Aug 20 04:57 PM
Dreyer Scott	EVP & Chief Commercial Officer	Aug 18 '25	Sale	38.21	16,389	626,171	103,613	Aug 20 04:57 PM
SANTINI GINO	Director	Aug 15 '25	Option Exercise	13.45	15,000	201,750	100,447	Aug 19 05:10 PM
SANTINI GINO	Director	Aug 15 '25	Sale	37.19	5,405	201,018	95,042	Aug 19 05:10 PM
Dreyer Scott	Officer	Aug 18 '25	Proposed Sale	38.21	16,389	626,170		Aug 18 04:50 PM
Dreyer Scott	EVP & Chief Commercial Officer	Aug 13 '25	Option Exercise	21.34	4,861	103,734	108,474	Aug 15 05:08 PM
Dreyer Scott	EVP & Chief Commercial Officer	Aug 13 '25	Sale	38.03	4,861	184,881	103,613	Aug 15 05:08 PM
Rubric Capital Management LP	10% Owner	Aug 13 '25	Sale	37.85	25,000	946,250	3,132,743	Aug 15 04:12 PM
SANTINI GINO	Director	Aug 15 '25	Proposed Sale	37.19	5,405	201,019		Aug 15 12:34 PM
Dreyer Scott	Officer	Aug 13 '25	Proposed Sale	38.03	4,861	184,881		Aug 13 04:31 PM
Freund John Gordon	Director	Aug 08 '25	Sale	34.36	11,659	400,641	23,129	Aug 12 05:18 PM
Heffernan Michael Thomas	Former Director	Jul 09 '25	Proposed Sale	32.17	10,328	332,269		Jul 09 04:10 PM
Heffernan Michael Thomas	Former Director	Jul 08 '25	Proposed Sale	31.38	790	24,792		Jul 08 04:19 PM
Heffernan Michael Thomas	Former Director	Jul 07 '25	Proposed Sale	31.25	14,210	444,062		Jul 07 04:43 PM
Heffernan Michael Thomas	Former Director	Jul 02 '25	Proposed Sale	30.30	25,000	757,380		Jul 02 04:50 PM
Melincoff Gwen A	Former Director	Jul 02 '25	Proposed Sale	30.29	47,082	1,425,971		Jul 02 04:35 PM
Freund John Gordon	Director	Jun 09 '25	Option Exercise	13.45	15,000	201,750	77,259	Jun 11 05:04 PM
Freund John Gordon	Director	Jun 09 '25	Sale	30.62	6,601	202,149	70,658	Jun 11 05:04 PM
Freund John Gordon	Director	Jun 09 '25	Proposed Sale	30.62	6,601	202,148		Jun 09 01:02 PM
Tupper Colleen	EVP & Chief Financial Officer	Mar 21 '25	Sale	30.03	6,396	192,069	156,667	Mar 24 05:06 PM
Tupper Colleen	EVP & Chief Financial Officer	Mar 20 '25	Sale	30.00	1,206	36,181	163,063	Mar 24 05:06 PM
Dreyer Scott	EVP & Chief Commercial Officer	Mar 21 '25	Sale	30.03	18,881	566,983	103,613	Mar 24 05:05 PM
Dreyer Scott	EVP & Chief Commercial Officer	Mar 20 '25	Sale	30.00	1,927	57,811	122,494	Mar 24 05:05 PM
Tupper Colleen	Officer	Mar 21 '25	Proposed Sale	30.03	6,396	192,069		Mar 21 04:35 PM
Dreyer Scott	Officer	Mar 21 '25	Proposed Sale	30.03	18,881	566,984		Mar 21 04:21 PM
Tupper Colleen	Officer	Mar 20 '25	Proposed Sale	30.00	1,206	36,181		Mar 20 04:32 PM
Kuhlmann Shirley R.	Former Officer	Mar 20 '25	Proposed Sale	29.65	40,494	1,200,632		Mar 20 04:19 PM
Dreyer Scott	Officer	Mar 20 '25	Proposed Sale	30.00	1,927	57,811		Mar 20 04:17 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Collegium Pharmaceutical Inc

Upgrade your FINVIZ experience